FUNDAMENTALS
EdgeFII/DII
CIPLACipla
₹1,415.00-0.25%
Terminal
  • Overview
  • Price
  • Ratios
  • About
  • P&L
  • Balance
  • Cash flow
  • Holders
  • Actions
  • Peers
  • News
CIPLANSE · EquityPharmaceuticals

Cipla

ISIN
INE059A01026
Instrument key
NSE_EQ|INE059A01026
Open in terminal Fundamentals cached for 6 hours
Last traded price
₹1,415.00-3.50 · -0.25%
Day rangecircuit ₹1,273.50 – ₹1,556.50
1,401.20
1,428.00

as of 21/11/2026, 1:30:44 pm

Open
₹1,418.50
Day high
₹1,428.00
Day low
₹1,401.20
Prev. close
₹1,418.50
Volume
14.84 L
VWAP
₹1,413.02

On this page

Company

  • Overview
  • Price chart
  • Key ratios
  • About

Statements

  • Profit & loss
  • Balance sheet
  • Cash flow

Ownership

  • Shareholding
  • Corporate actions
  • Peers

Market

  • News

02/Price history

Price chart

5 years · weekly candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.

1D1W1M
6M
1Y
5Y
MAX
Change · 5Y
+58.58%
892.30 → 1,415.00
Period high
₹1,702.05
7/10/2024
Period low
₹850.00
13/12/2021
From high
-16.86%
+66.47% from low
Avg volume
84.98 L
222.65 Cr total
Volatility · ann.
21.3%
262 candles · 138 up / 123 down
16 Nov 2026O 1,393.00H 1,435.00L 1,381.30C 1,415.00Vol 86.56 L
SMA 20SMA 50Averages need 50 candles before they begin
Candle data262 rows of open, high, low, close and volumeShowHide
16 Nov 20261,393.001,435.001,381.301,415.00+1.58%53.7086.56 L
9 Nov 20261,408.001,421.401,391.801,391.80-1.15%29.6061.36 L
2 Nov 20261,383.001,416.001,364.601,405.80+1.65%51.4072.82 L
26 Oct 20261,336.601,381.701,319.001,378.90+3.16%62.7092.02 L
19 Oct 20261,322.001,339.001,296.401,338.00+1.21%42.6045.89 L
12 Oct 20261,307.401,337.501,300.201,325.10+1.35%37.3043.60 L
5 Oct 20261,334.301,351.001,292.001,301.00-2.50%59.0037.13 L
28 Sept 20261,399.701,405.001,333.401,344.00-3.98%71.6041.76 L
21 Sept 20261,383.201,421.001,364.501,399.70+1.19%56.5050.61 L
14 Sept 20261,355.001,394.501,344.301,394.50+2.92%50.2042.54 L

Historical price and volume data · Showing 1–10 of 262

1 / 27

03/Valuation & returns

Key ratios vs sector

Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.

P/E

Price ÷ earnings per share

40.06
Company
40.06
Sector
-45.02

Worse than sector by 189%

P/B

Price ÷ book value per share

3.23
Company
3.23
Sector
4.21

Better than sector by 23%

ROA

Net income ÷ total assets

6.6%
Company
6.6%
Sector
1.19%

Better than sector by 455%

ROE

Net income ÷ shareholders' equity

8.18%
Company
8.18%
Sector
-0.4%

Better than sector by 2145%

ROCE

EBIT ÷ capital employed

10.8%
Company
10.8%
Sector
15.44%

Worse than sector by 30%

Quick Ratio

Liquid assets ÷ current liabilities

2.5
Company
2.5
Sector
4.8

Worse than sector by 48%

EV/EBITDA

Enterprise value ÷ EBITDA

21.64
Company
21.64
Sector
22.86

Better than sector by 5%

04/Business

About the company

Sector: Pharmaceuticals

Cipla Limited is an India-based global pharmaceutical company. The Company is engaged in manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). Its geographical segments include India, the United States, South Africa, and the Rest of the World. It has its network of manufacturing, trading and other incidental operations in India and International markets.

Sector market cap (INR)
₹1,14,312 Cr

reported in crore

Sector market cap (USD)
$12.70B

reported in billion

Market capitalisation is reported at the sector-constituent level, not the standalone company level.

05/Profit & loss

Standalone income statement

Annual figures in ₹ crore. Growth marked reported is provided; margins are derived.

YearlyQuarterly
ConsolidatedStandalone
Revenue · Mar 2026
₹20,103 Cr
+0.36% vs Mar 2025
Net profit · Mar 2026
₹3,515 Cr
-31.85% vs Mar 2025
Operating margin
23.1%
was 32.3%
Revenue CAGR · 4p
10.7%
profit 11.8% · op 15.5%
Filed order
Revenue20,10320,03017,64514,802
Revenue growthreported0.4%13.5%19.2%—
Operating profit4,6366,4694,9473,006
Operating profit growthreported-28.3%30.8%64.6%—
Operating marginderived23.1%32.3%28.0%20.3%
Net profit3,5155,1584,0772,513
Net profit growthreported-31.9%26.5%62.2%—
Net marginderived17.5%25.8%23.1%17.0%
EPS — basic₹/share, annual43.5263.8750.5131.15

Figures in ₹ crore. Margin rows are computed from the reported values.

06/Balance sheet

Standalone balance sheet

Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.

ConsolidatedStandalone
Total assets · Mar 2026
₹38,493 Cr
+8.23% YoY
Total liabilities
₹4,292 Cr
Net worth
₹34,201 Cr
Liabilities ÷ assets
11.2%
lower means a lighter balance sheet
Filed order
Total assets38,49335,56631,05327,596
Total liabilities4,2923,4663,0792,958
Net worthderived34,20132,09927,97424,638
Liabilities ÷ assetsderived11.2%9.7%9.9%10.7%
Asset growthderived8.2%14.5%12.5%—

Figures in ₹ crore. Stacked chart height equals total assets.

Full annual line itemsNon-current & current assets, liabilities, equity capitalShowHide
Filed order
Non-Current Assets20,58117,19716,19514,225
Current Assets17,91218,36914,85813,371
Total Assets38,49335,56631,05327,596
Current Liabilities3,8723,1832,8622,700
Net Current Asset14,04015,18611,99610,671
Non-Current Liabilities420283217259
Equity Capital34,20132,09927,97424,638
Total Equity & Liabilities38,49335,56631,05327,596

Figures in ₹ crore unless the line item is per-share.

07/Cash flow

Standalone cash flow

Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.

ConsolidatedStandalone
Operating · Mar 2026
₹2,832 Cr
-14.22% YoY
Investing
-₹1,344 Cr
Financing
-₹1,322 Cr
Free cash flow
₹1,488 Cr
operating + investing
Filed order
Operating activities2,8323,3013,7273,035
Operating changereported-14.2%-11.4%22.8%—
Investing activities-1,344-2,309-2,883-2,758
Investing changereported41.8%19.9%-4.5%—
Financing activities-1,322-1,074-709-425
Financing changereported-23.1%-51.5%-66.9%—
Net cash flowderived166-81135-148
Free cash flowoperating + investing1,488992844277

Figures in ₹ crore.

Full annual line itemsProfit before tax through closing cash balanceShowHide
Filed order
Profit before tax4,6366,4695,4323,685
Income before WC changes4,3915,8895,0893,955
Change in Assets-561-1,477-350134
Change in Liabilities22524821131
Change in WC-336-1,229-138165
Cash flow from Operations2,8323,3013,7273,035
Cash flow from Investing-1,344-2,309-2,883-2,758
Cash flow from Financing-1,322-1,074-709-425
Total Cash Flow166-81135-148
Cash (Start of the year)8316529177
Cash (End of the year)2498316529

Figures in ₹ crore unless the line item is per-share.

08/Ownership

Shareholding pattern

Percentage of total shares by holder category across the last 4 reported quarters. Sort any quarter column to rank holders by size.

Promoters
29.21%
0.00 pts QoQ
FII
20.25%
+0.04 pts QoQ
DII (other)
14.16%
+0.09 pts QoQ
Mutual funds
20.78%
+0.22 pts QoQ
Retail & others
15.61%
-0.34 pts QoQ
Filed order
Promoters29.2%29.2%29.2%29.2%
FII20.3%20.2%22.6%23.9%
DII (other)14.2%14.1%13.3%11.5%
Mutual funds20.8%20.6%18.7%19.2%
Retail & others15.6%15.9%16.3%16.1%
Promoters — QoQ changepts, derived0.0%0.0%0.0%—
FII — QoQ changepts, derived0.0%-2.3%-1.4%—
DII (other) — QoQ changepts, derived0.1%0.8%1.8%—
Mutual funds — QoQ changepts, derived0.2%1.9%-0.6%—
Retail & others — QoQ changepts, derived-0.3%-0.3%0.1%—
Totalderived100.0%100.0%100.0%100.0%

Values are percentages of total outstanding shares; QoQ rows are percentage-point moves.

09/Events

Corporate actions

Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.

DividendFinal₹13.00650.0%05 Jun 202605 Jun 202613 May 2026

10/Comparison

Peers & competitors

Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.

SUNPHARMASUN Pharmaceutical IND LPharmaceuticals₹1,884.90-0.79%19.16 L₹4,52,299 Cr$50.26B
DIVISLABDivi S Laboratories LtdPharmaceuticals₹11,180.50+0.02%4.05 L₹2,97,325 Cr$33.04B
TORNTPHARMTorrent Pharmaceuticals LPharmaceuticals₹4,689.50+1.70%2.00 L₹1,78,727 Cr$19.86B
LAURUSLABSLaurus Labs LimitedPharmaceuticals₹2,294.60-0.49%8.79 L₹1,24,002 Cr$13.78B
ZYDUSLIFEZydus Lifesciences LtdPharmaceuticals₹1,200.00-0.24%7.80 L₹1,19,207 Cr$13.25B
DRREDDYDR. Reddy S LaboratoriesPharmaceuticals₹1,390.20-0.76%8.31 L₹1,16,145 Cr$12.90B
MANKINDMankind Pharma LimitedPharmaceuticals₹2,665.00+1.37%4.56 L₹1,09,870 Cr$12.21B
AUROPHARMAAurobindo Pharma LtdPharmaceuticals₹1,799.00-0.37%8.11 L₹1,03,298 Cr$11.48B
LUPINLupin LimitedPharmaceuticals₹2,014.00+0.76%6.31 L₹91,916 Cr$10.21B
GLENMARKGlenmark PharmaceuticalsPharmaceuticals₹2,648.00+1.51%5.40 L₹74,733 Cr$8.30B

Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10

1 / 1

11/Coverage

Company news

Articles published in the last seven days, paginated by the provider.

5102050
  • Thumbnail: Why LIC, Adani Power, NSE, DMart and HAL are not in the NIFTY50 index despite their large market caps
    4h ago21/11/2026, 9:21:48 am
    Why LIC, Adani Power, NSE, DMart and HAL are not in the NIFTY50 index despite their large market caps

    Adani Power, LIC, Divi’s Laboratories, Hindustan Aeronautics, Adani Green Energy and others have high market capitalisation compared to the NIFTY50 bottom five stocks. But despite this, the stock is not part of the NIFTY50 index. Here’s why

  • Thumbnail: Top gainers and losers, Nov 18: Titan tumbles 4%, HDFC Life falls 3%, Cipla shares jump 3%; check list
    3d ago18/11/2026, 5:10:05 pm
    Top gainers and losers, Nov 18: Titan tumbles 4%, HDFC Life falls 3%, Cipla shares jump 3%; check list
Full annual line itemsRevenue, other income, expenses, tax, EPS
ShowHide
Filed order
Revenue18,98019,04516,57414,345
Other Income1,1239851,071457
Total Revenue20,10320,03017,64514,802
Total Expenses15,22213,85512,69811,611
Profit Before Tax4,6366,4694,9473,006
Tax1,1211,3111,233862
Profit After Tax3,5155,1583,7142,144
EPS - Basic43.5263.8750.5131.15
EPS - Diluted43.4963.8250.4631.12

This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.

On November 18, the 30-share BSE SENSEX slumped 500.38 points or 0.61% to close at 82,031.81, while the 50-share NIFTY fell by 159.45 points or 0.63% to end at 25,227.95.

Showing 1–2 of 2 articles